NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.

Sara Santana-HernándezJesús Suarez-OlmosSonia ServitjaPau Berenguer-MolinsMarcel Costa-GarciaLaura ComermaAnna ReaJulia Perera-BelSilvia MenendezOriol ArpíBegoña BermejoMaría Teresa MartínezJuan Miguel CejalvoIñaki Comino-MéndezJavier PascualEmilio AlbaMiguel López-BotetFederico RojoAna RoviraJoan AlbanellAura Muntasell

Published in: Journal of experimental & clinical cancer research : CR (2024)

This study identifies specialized NK cell subsets as the source of IFN-ɣ influencing the clinical efficacy of anti-HER2 antibodies. It also reveals the potential of serum CCL5/CXCL9 as biomarkers for identifying patients with NK cell-rich tumors and favorable responses to anti-HER2 antibody-based neoadjuvant treatment.

Keyphrases

nk cells
rectal cancer
immune response
lymph node
locally advanced
dendritic cells
liver injury
liver fibrosis
palliative care
genome wide
squamous cell carcinoma
risk assessment
drug induced
young adults
climate change
dna methylation